A Boost for HIV Vaccine Design

+ See all authors and affiliations

Science  13 Aug 2010:
Vol. 329, Issue 5993, pp. 770-773
DOI: 10.1126/science.1194693

You are currently viewing the summary.

View Full Text


A major roadblock to the development of an effective vaccine against the human immunodeficiency virus (HIV-1) is the lack of an immunogen that elicits broadly protective antibodies (1). Passive transfer studies in animal models have associated protection with neutralizing antibodies and, encouragingly, serum studies show that a subset of HIV-infected individuals produces potent broadly neutralizing antibodies (2). Understanding the viral targets of such antibodies and how they achieve potent and broad neutralization has become a key endeavor in HIV vaccine research. On page 856 of this issue, Wu et al. (3) describe the isolation of particularly potent monoclonal broadly neutralizing antibodies using a novel selection strategy, and on page 811, Zhou et al. (4) solve the crystal structure of the most effective of these antibodies in complex with its target gp120, a viral envelope glycoprotein. These studies further invigorate the currently active field of discovering broadly neutralizing antibodies against HIV (2, 57) and provide valuable molecular information for rational vaccine design.

Related Content